186 850

Cited 0 times in

The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment.

Authors
Kim, SK; Hur, KY; Kim, HJ; Shim, WS; Ahn, CW; Park, SW; Cho, YW; Lim, SK; Lee, HC; Cha, BS
Citation
European journal of endocrinology, 157(2):167-174, 2007
Journal Title
European journal of endocrinology
ISSN
0804-46431479-683X
Abstract
OBJECTIVE: The goal was to investigate the interrelationships between the hypoglycemic effects of rosiglitazone and the changes in the regional adiposity of type 2 diabetic patients.



DESIGN AND METHODS: We added rosiglitazone (4 mg/day) to 173 diabetic patients (111 males and 62 females) already taking a stable dose of conventional antidiabetic medications except for thiazolidinediones. The abdominal fat distribution was assessed by ultrasonography at baseline and 12 weeks later. Using ultrasonographic images, the s.c. and visceral fat thickness (SFT and VFT respectively) were measured.



RESULTS: Rosiglitazone treatment for 3 months improved the glycemic control. However, the response to rosiglitazone was no more than 36.4%; the deterioration of the glycemic control was found in 16.8% of subjects. In addition, rosiglitazone treatment significantly increased the body fat mass, especially the s.c. fat. However that did not alter the visceral fat content. The percentage changes in fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) concentrations after treatment were inversely correlated with the increase in SFT (r=-0.327 and -0.353, P<0.001 respectively) and/or body weight (r=-0.316 and -0.327, P<0.001 respectively). Multiple regression analysis revealed that the improvement in the FPG after rosiglitazone treatment was correlated with the baseline FPG (P<0.001) and the change in the SFT (P=0.019), and the reduction in the HbA1c was related with the baseline FPG (P=0.003) and HbA1c (P<0.001) and the changes in the SFT (P=0.010) or VFT (P=0.013).



CONCLUSIONS: The increase in the s.c. fat depot after rosiglitazone treatment may be an independent factor that determines the hypoglycemic efficacy.
MeSH terms
Abdominal Fat/physiology*Abdominal Fat/ultrasonographyBlood Glucose/metabolism*Body Composition/physiologyDiabetes Mellitus, Type 2/bloodDiabetes Mellitus, Type 2/drug therapyDiabetes Mellitus, Type 2/physiopathologyFemaleHemoglobin A, Glycosylated/metabolismHumansHypoglycemic Agents/therapeutic use*Lipid Metabolism/drug effectsMaleMiddle AgedRegression AnalysisThiazolidinediones/therapeutic use*
DOI
10.1530/EJE-07-0043
PMID
17656594
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Endocrinology & Metabolism
AJOU Authors
김, 혜진
Full Text Link
Files in This Item:
Full-Text Not Available.txtDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse